Fig. 6

AXL influences TBI-induced neuroinflammation and neurological impairments. (A) Inflammation cytokines are determined at 3 dpi under drug treatment. IL-6/TNFα/IL-1β were upregulated at 3 dpi and rmGas6 treatment attenuated the inflammation upregulation, whereas R428 treatment intensified neuroinflammation. **p < 0.01 versus sham, ^#p < 0.05, ^##p < 0.01 versus vehicle by one-way ANOVA. (B) Drug treatment mediates TBI-induced body weight changes. The relative change of body weight was calculated by comparing with 0 dpi. *p < 0.01 versus sham, ^#p < 0.05, ^##p < 0.01 versus vehicle group by two-way ANOVA. (C) Motor coordination was reduced by TBI, and the disorder was enhanced by R428 treatment while rmGas6 attenuated this change. **p < 0.01, *p < 0.05 versus sham, ^##p < 0.01 versus vehicle by two-way ANOVA. (D) Temporal neurological function assessment of mice suffered TBI at different time points by using modified neurological severity score test (mNSS). **p < 0.01 versus sham, ^##p < 0.01 versus 1 dpi by one-way ANOVA. (E) mNSS at 3 dpi under drug treatment. **p < 0.01 by one-way ANOVA. (F) Depressive-like behavior was determined after TBI with/ without drug administration by time spent immobile in the TST at 7 dpi (left) and 14 dpi (right). All data are presented as mean ± SD; (n = 6). **p < 0.01 versus sham, ^##p < 0.01 versus vehicle by one-way ANOVA